GA, or geographic atrophy, is a serious eye condition that represents the most advanced stage of dry age-related macular degeneration (AMD). It gradually destroys cells in the central part of the retina, leading to permanent blind spots in your central vision. About 5 million people worldwide have geographic atrophy, and until recently, no treatments existed to slow it down.
How Geographic Atrophy Develops
Your retina has a thin layer of support cells called the retinal pigment epithelium, or RPE. These cells nourish the light-sensing photoreceptors that make vision possible and help clear out cellular waste. In geographic atrophy, the RPE cells die off in expanding patches, and once they’re gone, the photoreceptors above them and the blood vessel layer beneath them die too. The result is a growing “map-like” area of dead tissue on the retina, which is how the condition got the name “geographic.”
The immune system plays a central role. A branch of your body’s defense system called the complement pathway appears to become overactive in the retina, contributing to the damage. Genetic variations in complement pathway genes are strongly linked to developing advanced AMD, though researchers have found that complement activity alone may not be what drives the lesions to keep expanding once they’ve formed. The process is slow but relentless: patches of atrophy typically grow by about 1 to 2 square millimeters per year.
What GA Looks Like From the Inside
Geographic atrophy affects your central vision, the sharp, detailed vision you use for reading, recognizing faces, and driving. Early on, you might not notice symptoms at all if the atrophy starts away from the very center of the retina (the fovea). As the dead zones expand, though, you may notice:
- Blind spots in your central field. Words on a page might disappear, or parts of a face may seem missing.
- Difficulty in dim lighting. Tasks like navigating a dimly lit restaurant become harder.
- Reduced contrast sensitivity. It becomes tough to distinguish objects from similarly colored backgrounds.
- Need for brighter light. Reading and close-up work require more and more illumination over time.
GA does not typically cause complete blindness. Peripheral vision usually remains intact, so you can still get around. But the loss of central vision can make daily tasks like reading, cooking, and driving extremely difficult or impossible.
Who Is at Risk
The biggest risk factor is age. Geographic atrophy overwhelmingly affects people over 60, and risk climbs steeply after 75. Beyond age, several factors raise your chances significantly.
Smoking is one of the strongest modifiable risk factors. Data from the Blue Mountains Eye Study found that past smokers had roughly a 3-fold higher risk of developing geographic atrophy compared to people who never smoked. The risk was even higher for current smokers, especially those who also had low levels of “good” HDL cholesterol or ate little fish. Genetics matter too: variations in genes related to the complement immune pathway substantially increase susceptibility to advanced AMD, including GA. Family history of macular degeneration is a meaningful warning sign.
How GA Is Diagnosed
Eye doctors diagnose geographic atrophy using specialized retinal imaging, not just a standard eye exam. Two techniques are the workhorses of GA diagnosis and monitoring. Fundus autofluorescence (FAF) uses a blue light to make the retina’s support cells glow naturally. Dead zones show up as dark patches because the cells that would normally fluoresce are gone. This gives a clear map of atrophy size and location.
Optical coherence tomography (OCT) takes cross-sectional scans of the retina, almost like an ultrasound but using light. It reveals the specific layers of tissue that have been lost, including RPE cells, photoreceptors, and the blood vessel layer beneath. Together, these two imaging tools let your doctor measure the exact area of atrophy and track how fast it’s growing over time, which is critical for treatment decisions.
Treatments Approved in 2023
For decades, there was no treatment for geographic atrophy. That changed in 2023 when the FDA approved two drugs: Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol). Both work by dialing down the overactive complement immune pathway that contributes to retinal cell death. Both require injections directly into the eye, either monthly or every other month, on an ongoing basis.
These treatments slow the growth of atrophy patches but do not reverse damage that has already occurred. In clinical trials, both drugs reduced the rate of lesion expansion compared to placebo. A comparative analysis across the major phase 3 trials (OAKS, DERBY, and GATHER2) found that Syfovre reduced lesion growth by about 30% more than Izervay when results were pooled, though the comparison involved indirect statistical methods rather than a head-to-head trial. The key takeaway is that both drugs meaningfully slow progression, but neither stops it entirely, and neither restores lost vision.
Eye injections sound intimidating, but the procedure is routine. Your eye is numbed beforehand, and the injection itself takes seconds. The bigger commitment is the treatment schedule: you’ll need to return to your retina specialist regularly for as long as the treatment continues.
The Role of AREDS2 Supplements
You may have heard of AREDS2 vitamins, a specific antioxidant and mineral formula developed through NIH-funded research. These supplements (containing vitamins C and E, lutein, zeaxanthin, zinc, and copper) have long been recommended to slow progression from intermediate AMD to late-stage disease. But their role in geographic atrophy specifically has been less clear.
A re-analysis of the original AREDS trial data found that the supplements also helped people who already had geographic atrophy, with an important caveat. For people whose atrophy started away from the center of the retina, the supplements slowed the expansion of dead zones toward the fovea by approximately 55% over three years. That’s a substantial benefit. However, for those whose atrophy had already reached the central fovea, the supplements offered little additional protection. This means starting supplements early, ideally at the intermediate AMD stage or as soon as GA is detected away from the center, offers the best chance of preserving central vision longer.
Living With Geographic Atrophy
Because GA progresses slowly, most people have time to adapt. Low-vision aids like magnifying glasses, large-print devices, tablets with adjustable text size, and high-contrast settings on phones can help maintain independence. Many people with GA continue to live on their own and stay active, though they may need to give up driving as central vision worsens.
Monitoring is essential even after diagnosis. Your doctor will want to track lesion growth with regular imaging, both to assess whether treatment is working and to watch for “wet” AMD, a different form of macular degeneration that can develop alongside GA and requires separate, urgent treatment. If you notice a sudden change in vision, such as straight lines appearing wavy or a rapid increase in blind spots, that warrants a prompt visit rather than waiting for your next scheduled appointment.